2.0 ATA Hyperbaric Chamber: The Clinical Standard Explained

A 2.0 ATA hyperbaric chamber is the standard clinical starting pressure for most UHMS-approved medical indications. It is the most commonly used pressure in hyperbaric medicine, a 2024 UHMS survey found that 27.1% of members use 2.0 ATA exclusively, and for conditions including radiation cystitis, diabetic foot ulcers, and chronic osteomyelitis, 68 to 75% of clinicians selected 2.0 ATA as their preferred pressure.¹

At 2.0 ATA with 100% oxygen, arterial O₂ reaches approximately 2.0 ATA partial pressure, well above the 1.5 ATA bacteriostatic threshold, far above soft chamber levels (1.3 ATA with air), and at the lower end of the clinical range where extensive evidence exists.

What 2.0 ATA Delivers

2.0 ATA is clinically significant because it represents the minimum pressure for most UHMS-approved indications, produces measurably higher tissue oxygenation than lower pressures, and generates fewer adverse events than higher clinical pressures (2.4 to 3.0 ATA).

A 2023 study directly measured tissue oxygen in chronic wound patients at 1.4 ATA versus 2.0 ATA. Mean TcPO₂ was 161 mmHg at 1.4 ATA and 333 mmHg at 2.0 ATA, more than double, p<0.001. The authors found no evidence that 1.4 ATA benefits chronic ulcer patients.²

2.0 ATA vs Adjacent Pressures

The data shows that 2.0 ATA is not inferior to higher clinical pressures for most conditions, and carries fewer adverse events. For most standard clinical applications, 2.0 ATA is the evidence-based choice.

Chambers That Operate at 2.0 ATA

Standard clinical chambers from Perry Baromedical and Sechrist Industries operate at 2.0 to 3.0 ATA. For home and clinic environments seeking 2.0 ATA without full hospital infrastructure, options include:

Adverse Events at 2.0 ATA

A 2024 UHMS survey found the most common adverse events across clinical pressures: temporary myopia (24.4%), ear barotrauma (14.9%), and confinement anxiety (11.5%).¹ At 2.0 ATA, these rates are present but lower than at 2.4+ ATA. The decision to use 2.0 versus higher pressures should weigh evidence for the specific condition against the incremental adverse event risk at higher pressures.

For buying a 2.0 ATA chamber, see the 2.0 ATA hyperbaric chamber for sale guide. For the 1.5 ATA option, see the 1.5 ATA hyperbaric chamber guide. For hard shell clinical chambers at full clinical specifications, see the hard shell hyperbaric chamber guide.

FAQs

Is 2.0 ATA the standard for clinical HBOT?
It is the most commonly used pressure. 27.1% of UHMS members use 2.0 ATA exclusively. Some protocols use 2.4 ATA, particularly for decompression illness and CO poisoning. Pressure selection depends on the condition.

Is 2.0 ATA better than 2.4 ATA?
For most wound care and radiation injury indications, clinical data shows comparable outcomes. 2.0 ATA typically requires slightly more sessions but produces fewer adverse events at 2.5 ATA and above.

Can I get a 2.0 ATA chamber for home use?
Yes, OxyRevo Space60, Zeugma Monoplace Pro, and Dr Hugo Rejuven S200 all reach 2.0 ATA. None are FDA-cleared. CE certification applies to EU markets. Consider this carefully for US home use.

References

References

1. Laspro M et al. HBOT regimens, treated conditions, and adverse effect profile: UHMS survey. Undersea Hyperb Med. 2024. PMID: 39821765.
2. Sack RA et al. Transcutaneous oximetry in chronic ulcer patients at 1.4 vs 2.0 ATA. Undersea Hyperb Med. 2023. PMID: 38615347.
3. Ajayi OD et al. Comparison of two HBO regimens: 2.0 ATA vs 2.4 ATA in radiation cystitis. Undersea Hyperb Med. 2020. PMID: 33227834.
4. Soriano VH et al. Outcomes of HBOT at 2.0 vs 2.5 ATA for hemorrhagic radiation cystitis. Neurourol Urodyn. 2026. PMID: 41603214.
5. Harch P. Systematic review and dosage analysis: HBOT in mTBI PCS. Front Neurol. 2022. PMID: 35370898.

Clinical Use Cases at 2.0 ATA

The 2024 UHMS member survey provides the clearest picture of which conditions clinicians treat at 2.0 ATA versus higher pressures:

• Diabetic foot ulcers: 68% of clinicians select 2.0 ATA as the treatment pressure. Standard protocol is 90-minute sessions, 5 days per week, for 30 to 40 sessions. The evidence base at this pressure is extensive, with multiple RCTs demonstrating wound healing acceleration.
• Chronic refractory osteomyelitis: 75% of clinicians prefer 2.0 ATA. Treatment courses are longer, typically 40 to 60 sessions, reflecting the time needed for bone tissue response to hyperoxygenation.
• Radiation cystitis: A direct comparison of 2.0 ATA vs. 2.4 ATA (Ajayi et al. 2020) found similar response rates (72.7% vs. 78.3%, p=0.74). The 2.0 ATA group required slightly more sessions (45 vs. 40) but the clinical difference was not significant.
• Delayed radiation injury (soft tissue): Most clinicians use 2.0 to 2.4 ATA. The 2026 Soriano study comparing 2.0 and 2.5 ATA found similar efficacy with more adverse events at the higher pressure, further supporting 2.0 ATA as the default choice.
• Carbon monoxide poisoning: This is an exception. Most protocols call for 2.4 to 3.0 ATA for CO poisoning, based on evidence that higher pressures more rapidly displace CO from hemoglobin. 2.0 ATA is generally not used for this indication.

2.0 ATA Chambers for Home and Clinic Use

Traditionally, 2.0 ATA meant a hospital chamber. That is changing. Several manufacturers now offer chambers rated at 2.0 ATA that fit in clinical office space or large home installations:

• OxyRevo Space60 ($42,999): A sitting-position hard shell chamber rated at 1.5 to 2.0 ATA with CE marking. The 60-inch width accommodates two users. This is the most established option for non-hospital 2.0 ATA treatment, though it lacks FDA clearance.
• Macy-Pan HP2202-90 ($25,000 to $35,000): A lying-position hard shell chamber rated at 2.0 ATA with CE and ISO 13485 certification. Standard clinical configuration with acrylic viewing window.
• Dr Hugo / LANNX Rejuven S200 ($8,000 to $12,000): A soft shell chamber claiming 2.0 ATA rating with CE and ISO 13485 certification. [VERIFY: Soft shell chambers at 2.0 ATA are uncommon; verify actual achievable pressure and safety certification before purchase.]

A critical distinction: FDA clearance versus CE marking. FDA-cleared chambers have undergone the US regulatory process. CE-marked chambers meet European standards but have not been evaluated by the FDA. For personal use in the US, both are legally purchasable, but hospital-grade chambers from Perry Baromedical and Sechrist Industries remain the gold standard for clinical applications.

What Are the Side Effects and Risks?

One of the advantages of 2.0 ATA versus higher clinical pressures is a lower adverse event rate. The most common side effects of HBOT are pressure-related ear and sinus barotrauma and oxygen toxicity effects. Both are dose-dependent, meaning they increase with pressure and treatment duration.

At 2.0 ATA, barotrauma rates are lower than at 2.4 or 3.0 ATA because the pressure differential during compression and decompression is smaller. Oxygen toxicity risk is also reduced: seizures from oxygen toxicity are extremely rare at 2.0 ATA (estimated at less than 1 in 10,000 treatments) compared to a higher incidence at 2.8 to 3.0 ATA.

For patients comparing 1.5 ATA and 2.0 ATA options, the tissue oxygenation data is clear: mean TcPO2 at 2.0 ATA is 333 mmHg versus 161 mmHg at 1.4 ATA (the closest studied pressure to 1.5 ATA). That more-than-double increase in tissue oxygen comes with a modest increase in adverse event risk that most clinicians consider well justified for conditions that respond to HBOT.

Seph Fontane Pennock

Author

Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.

Website